Status:
COMPLETED
IL-2 Signaling and Polarization of Regulatory LBs: Involvement in Multiple Sclerosis
Lead Sponsor:
Rennes University Hospital
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Multiple sclerosis (MS) has long been considered a disease mediated primarily by CD4+ T cells. However, recent clinical trials demonstrating significant efficacy of B-lymphocyte depletive therapies ha...
Detailed Description
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that is the leading cause of non-traumatic disability in young adults. Pathophysiopathologically, MS has long been ...
Eligibility Criteria
Inclusion
- About the patients,Inclusion Criteria :
- Patients at the onset of illness :
- With a strong suspicion of MS requiring an LP to confirm the diagnosis (suggestive neurological symptoms AND more than two typical lesions on MRI) ; OR
- MS patients (untreated RR, SP or PP) :
- With MS that meets the MacDonald 2017 criteria;
- With relapsing-remitting (RR), secondary-progressive (SP) or primary-progressive (PP) MS; OR
- Non-MS patients :
- Presenting a non MS neurological inflammatory disease (meningitis, neurolupus, neurosarcoidosis, autoimmune encephalitis, acute polyradiculoneuritis);
- Benefiting from an LP for diagnostic or monitoring purposes;
- AND
- At least 18 years old;
- Without immunomodulating or immunosuppressive background treatment for at least 3 months;
- Without systemic corticosteroid treatment for at least 3 months;
- Having signed a free, informed and written consent.
- Affiliated with a social security system
- About healthy volunteers, inclusion criteria :
- At least 18 years old;
- Having signed a free, informed and written consent.
- Affiliated with a social security system
- Exclusion Criteria:
- For all groups
- Pregnancy ;
- Breastfeeding ;
- Persons of full age subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty.
- Healthy volunteers :
- Absence of autoimmune pathologies
- Without immunomodulating or immunosuppressive background treatment for at least 3 months;
- Without systemic corticosteroid treatment for at least 3 months.
Exclusion
Key Trial Info
Start Date :
March 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 23 2023
Estimated Enrollment :
95 Patients enrolled
Trial Details
Trial ID
NCT04697407
Start Date
March 23 2021
End Date
May 23 2023
Last Update
May 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Rennes
Rennes, France